These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 15167440)

  • 21. Sympathetic overactivity--the Cinderella of cardiovascular risk factors in dialysis patients.
    Vonend O; Rump LC; Ritz E
    Semin Dial; 2008; 21(4):326-30. PubMed ID: 18627567
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fetal origins of insulin resistance and the metabolic syndrome: a key role for adipose tissue?
    Meas T
    Diabetes Metab; 2010 Feb; 36(1):11-20. PubMed ID: 19815442
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Sympathetic system hyperactivity in obesity].
    Carvalheira JB
    Arq Bras Endocrinol Metabol; 2008 Feb; 52(1):6-7. PubMed ID: 18345391
    [No Abstract]   [Full Text] [Related]  

  • 24. [Hyperleptinemia, hyperinsulinemia and metabolic syndrome in cardiovascular risk: one for all and all for one].
    Botella Carretero JI
    Med Clin (Barc); 2004 Dec; 123(20):780-1. PubMed ID: 15607071
    [No Abstract]   [Full Text] [Related]  

  • 25. Low birth weight and increased cardiovascular risk: fetal programming.
    Balci MM; Acikel S; Akdemir R
    Int J Cardiol; 2010 Sep; 144(1):110-1. PubMed ID: 19171387
    [No Abstract]   [Full Text] [Related]  

  • 26. Sympathetic nervous system as a target for aging and obesity-related cardiovascular diseases.
    Balasubramanian P; Hall D; Subramanian M
    Geroscience; 2019 Feb; 41(1):13-24. PubMed ID: 30519806
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Childhood Psychological Distress as a Mediator in the Relationship Between Early-Life Social Disadvantage and Adult Cardiometabolic Risk: Evidence From the 1958 British Birth Cohort.
    Winning A; Glymour MM; McCormick MC; Gilsanz P; Kubzansky LD
    Psychosom Med; 2016; 78(9):1019-1030. PubMed ID: 27763989
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Time spent in sedentary posture is associated with waist circumference and cardiovascular risk.
    Tigbe WW; Granat MH; Sattar N; Lean MEJ
    Int J Obes (Lond); 2017 May; 41(5):689-696. PubMed ID: 28138134
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of dietary weight loss on sympathetic activity and cardiac risk factors associated with the metabolic syndrome.
    Straznicky NE; Lambert EA; Lambert GW; Masuo K; Esler MD; Nestel PJ
    J Clin Endocrinol Metab; 2005 Nov; 90(11):5998-6005. PubMed ID: 16091482
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sympathetic neural activity in hypertension and related diseases.
    Grassi G
    Am J Hypertens; 2010 Oct; 23(10):1052-60. PubMed ID: 20651696
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk factors related to cardiovascular diseases and the metabolic syndrome in multiple sclerosis - a systematic review.
    Wens I; Dalgas U; Stenager E; Eijnde BO
    Mult Scler; 2013 Oct; 19(12):1556-64. PubMed ID: 24048545
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sympathetic nervous system dysfunction: a common pathway linking skin and heart morbidity?
    Mastrolonardo M
    J Am Acad Dermatol; 2008 Feb; 58(2):352. PubMed ID: 18222338
    [No Abstract]   [Full Text] [Related]  

  • 33. [Metabolic syndrome].
    Kiyohara Y; Doi Y; Ninomiya T
    Nihon Naika Gakkai Zasshi; 2006 Sep; 95(9):1710-5. PubMed ID: 17037303
    [No Abstract]   [Full Text] [Related]  

  • 34. [Stress, cardiovascular disease and hypertension].
    Armario P; Hernández Del Rey R; Martín-Baranera M
    Med Clin (Barc); 2002 Jun; 119(1):23-9. PubMed ID: 12062003
    [No Abstract]   [Full Text] [Related]  

  • 35. [Muscle sympathetic nerve activity in cardiovascular disease].
    Miyajima E; Tochikubo O; Ishii M
    Jpn Circ J; 1993; 57 Suppl 4():1165-8. PubMed ID: 7966938
    [No Abstract]   [Full Text] [Related]  

  • 36. The deadly line linking sympathetic overdrive, dipping status and vascular risk: critical appraisal and therapeutic implications.
    Santilli F; Simeone P; D'Ardes D; Davì G
    Hypertens Res; 2016 Jun; 39(6):404-6. PubMed ID: 26984299
    [No Abstract]   [Full Text] [Related]  

  • 37. Metabolic syndrome: is there a pathophysiological common denominator?
    Tataranni PA
    World Rev Nutr Diet; 2005; 94():75-83. PubMed ID: 16145253
    [No Abstract]   [Full Text] [Related]  

  • 38. Introduction: addressing cardiometabolic risk.
    Haines ST
    Pharmacotherapy; 2006 May; 26(5 Pt 2):1S-2S. PubMed ID: 16715597
    [No Abstract]   [Full Text] [Related]  

  • 39. Reliability of heart rate as neuroadrenergic marker in the metabolic syndrome.
    Quarti Trevano F; Seravalle G; Macchiarulo M; Villa P; Valena C; Dell'Oro R; Mancia G; Grassi G
    J Hypertens; 2017 Aug; 35(8):1685-1690. PubMed ID: 28350577
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of sympathovagal imbalance with cardiovascular risks in patients with polycystic ovary syndrome.
    Kuppusamy S; Pal GK; Habeebullah S; Ananthanarayanan PH; Pal P
    Endocr Res; 2015; 40(1):37-43. PubMed ID: 24866562
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.